Publications
5674 Results
- Journal / Conference
- J Clin Oncol 37(suppl; abstr 4506); ASCO Annual Meeting (May 31-June 4, 2019, Chicago, IL), oral
- Year
- 2019
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1314
SWOG S1314: A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
- Journal / Conference
- J Clin Oncol 37(suppl; abstr 6516); American Society of Clinical Oncology (5/31/2019 - 6/4/2019, Chicago IL), oral
- Year
- 2019
- Research Committee(s)
- Cancer Care Delivery
- Study Number(s)
- S1105
Randomized Trial of Text-Messaging to Reduce Early Discontinuation of Adjuvant Aromatase Inhibitor Therapy in Women with Early Stage Breast Cancer: SWOG S1105, NCT01515800
- Journal / Conference
- J Clin Oncol 37(suppl; abstr 9022); ASCO (5/31/2019-6/4/2019, Chicago IL), poster discussion
- Year
- 2019
- Research Committee(s)
- Lung
- Study Number(s)
- S1400G
A Phase II Study of Talazoparib (BMN 673) in Patients with Homologous Recombination Repair Deficiency (HRRD) Positive Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub- Study, S1400G)
- Journal / Conference
- J Clin Oncol 37(suppl; abstr 9075); American Society of Clinical Oncology (5/31/19-6/4/19, Chicago IL), poster session
- Year
- 2019
- Research Committee(s)
- Lung
- Study Number(s)
- S1400K
Phase II study of ABBV-399 (Process II) in patients with C-MET positive stage IV/recurrent lung squamous cell cancer (SCC): LUNG-MAP sub-study S1400K (NCT03574753)
- Journal / Conference
- J Clin Oncol 37(suppl; abstr 9014); ASCO (5/31/19-6/4/19, Chicago IL), poster discussion
- Year
- 2019
- Research Committee(s)
- Lung
- Study Number(s)
- S1400I
A phase III randomized study of nivolumab plus ipilimumab versus nivolumab for previously treated patients with stage IV squamous cell lung cancer and no matching biomarker (Lung-MAP Sub-Study S1400I, NCT02785952).
- Journal / Conference
- J Clin Oncol 37(suppl; abstr TPS6652); American Society of Clinical Oncology (5/31/19-6/4/19, Chicago IL), TIPS, poster session
- Year
- 2019
- Research Committee(s)
- Cancer Care Delivery
- Study Number(s)
- S1417CD
Design and Accrual of SWOG S1417CD: Development of a Prospective Financial Impact Assessment Tool in Patients with Metastatic Colorectal Cancer (mCRC)
- Journal / Conference
- J Clin Oncol 37(suppl; abstr 9021); American Society of Clinical Oncology (5/31/19-6/4/19, Chicago IL), poster discussion
- Year
- 2019
- Research Committee(s)
- Lung
- Study Number(s)
- S1507
S1507: Phase II study of docetaxel and trametinib in patients with G12C or non-G12C KRAS mutation positive (+) recurrent non-small cell lung cancer (NSCLC)
- Journal / Conference
- J Clin Oncol 37(suppl; abstr 4137); American Society of Clinical Oncology (5/31/19 - 6/4/19, Chicago IL), poster session
- Year
- 2019
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- S1505
SWOG S1505: Initial Findings on Eligibility and Neoadjuvant Chemotherapy Experience with mFOLFIRINOX versus Gemcitabine/nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
- Journal / Conference
- J Clin Oncol 37(suppl; abstr 4014); American Society of Clinical Oncology (5/31-6/4/19, Chicago IL), poster discussion
- Year
- 2019
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- S1513
Randomized Phase II Study of 2nd Line Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) vs FOLFIRI in Metastatic Pancreatic Cancer (mPC): SWOG S1513
- Journal / Conference
- J Clin Oncol 37(suppl; abstr TPS2658); ASCO (5/31-6/4/2019, Chicago IL), TIPS, poster session
- Year
- 2019
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- Study Number(s)
- S1609